Close
Nordic 9Nordic 9

Thomas Würdinger (investor - Angel Investor)

Netherlands
See something wrong or missing? Let us know
Offices:Amsterdam
Average round investment:5.36M USD
Average number per year:1.0
Distribution: 2022 (1)
Portfolio companies: Netherlands CimCure
Mostly invests in: Netherlands Netherlands (1) Biotech (1)

1 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Thomas Würdinger

Name Criteria
United States Life Science Angels
83%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Netherlands Positron Ventures
83%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Netherlands Thuja Capital Management B.V.
82%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Spain Ekarpen
80%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Germany Peppermint Venture Partners
80%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Rhia Ventures
80%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Thomas Feldthus
80%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Hong Kong MCG Technology Group
80%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Luxembourg Magna Capital Partners
80%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Norway RadForsk
80%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.1
  • Active last 12 months: Yes
Top